<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Verastem Inc — News on 6ix</title>
<link>https://6ix.com/company/verastem-inc</link>
<description>Latest news and press releases for Verastem Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/verastem-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d47b78dffbe2df120fd0.webp</url>
<title>Verastem Inc</title>
<link>https://6ix.com/company/verastem-inc</link>
</image>
<item>
<title>Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
<pubDate>Thu, 23 Apr 2026 11:30:00 GMT</pubDate>
<description>BOSTON, April 23, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET.</description>
</item>
<item>
<title>Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-two-year-median-follow-up-data-on-avmapkir-fakzynjar-combination-therapy-avutometinib-capsules-defactinib-tablets-in-recurrent-low-grade-serous-ovarian-cancer-at-the-sgo-2026-annual-meeting-on-womens-cancers</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-two-year-median-follow-up-data-on-avmapkir-fakzynjar-combination-therapy-avutometinib-capsules-defactinib-tablets-in-recurrent-low-grade-serous-ovarian-cancer-at-the-sgo-2026-annual-meeting-on-womens-cancers</guid>
<pubDate>Fri, 10 Apr 2026 04:00:00 GMT</pubDate>
<description>Patients in the Phase 2 RAMP 201 clinical trial demonstrated sustained clinical benefits across multiple efficacy measures highlighting durability of</description>
</item>
<item>
<title>Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-abstracts-accepted-for-presentation-on-avmapkitm-fakzynjatm-avutometinib-capsules-defactinib-tablets-combination-therapy-at-the-society-of-gynecologic-oncology-2026-annual-meeting-on-womens-cancers</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-abstracts-accepted-for-presentation-on-avmapkitm-fakzynjatm-avutometinib-capsules-defactinib-tablets-combination-therapy-at-the-society-of-gynecologic-oncology-2026-annual-meeting-on-womens-cancers</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trial</description>
</item>
<item>
<title>Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-late-breaking-and-regular-abstracts-accepted-for-presentation-at-the-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-late-breaking-and-regular-abstracts-accepted-for-presentation-at-the-aacr-annual-meeting-2026</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Preclinical research with VS-7375 in combination with PRMT5 inhibitors demonstrated strong durable tumor regressions in KRAS G12D pancreatic cancer models In</description>
</item>
<item>
<title>Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-business-updates-85</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-business-updates-85</guid>
<pubDate>Wed, 04 Mar 2026 21:01:00 GMT</pubDate>
<description>BOSTON, March 04, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the three months and full year ended December 31, 2025, and highlighted recent progress.</description>
</item>
<item>
<title>Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-report-fourth-quarter-123000371</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-report-fourth-quarter-123000371</guid>
<pubDate>Wed, 18 Feb 2026 12:30:00 GMT</pubDate>
<description>BOSTON, February 18, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET.</description>
</item>
<item>
<title>Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-provides-preliminary-fourth-123000766</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-provides-preliminary-fourth-123000766</guid>
<pubDate>Wed, 04 Feb 2026 12:30:00 GMT</pubDate>
<description>BOSTON, February 04, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced preliminary, unaudited fourth quarter and full year 2025 net product revenues for AVMAPKI™ FAKZYNJA™ CO-PACK, business updates, and 2026 priorities.</description>
</item>
<item>
<title>Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-inducement-grants-210100605</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-inducement-grants-210100605</guid>
<pubDate>Mon, 12 Jan 2026 21:01:00 GMT</pubDate>
<description>BOSTON, January 12, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 shares of its common stock to eight new employees and the grant of 218,265 restricted stock units to nineteen new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of emplo</description>
</item>
<item>
<title>Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-provides-update-ramp-203-phase-1-2-clinical-trial-advanced-kras</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-provides-update-ramp-203-phase-1-2-clinical-trial-advanced-kras</guid>
<pubDate>Mon, 29 Dec 2025 05:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK</description>
</item>
<item>
<title>Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-strategic-transition-plan-accelerate-next-phase-growth</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-strategic-transition-plan-accelerate-next-phase-growth</guid>
<pubDate>Mon, 15 Dec 2025 05:00:00 GMT</pubDate>
<description>John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of</description>
</item>
<item>
<title>Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-present-8th-annual-evercore-healthcare-conference-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-present-8th-annual-evercore-healthcare-conference-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK</description>
</item>
<item>
<title>Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-pricing-90-million-public-offering-common-stock-and-pre</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-pricing-90-million-public-offering-common-stock-and-pre</guid>
<pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK</description>
</item>
<item>
<title>Verastem Oncology Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-proposed-public-offering-common-stock-2025-11-13</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-proposed-public-offering-common-stock-2025-11-13</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK</description>
</item>
<item>
<title>Verastem Oncology to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-present-upcoming-investor-conferences-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-present-upcoming-investor-conferences-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK</description>
</item>
<item>
<title>Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-reports-third-quarter-2025-financial-results-and-highlights-recent</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-reports-third-quarter-2025-financial-results-and-highlights-recent</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $11.2 million VS-7375 cleared first two monotherapy dose levels with no dose-limiting toxicities</description>
</item>
<item>
<title>Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-encouraging-preliminary-data-ongoing-phase-1-2a-dose</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-encouraging-preliminary-data-ongoing-phase-1-2a-dose</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reported Promising anti-tumor activity observed in</description>
</item>
<item>
<title>Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-report-third-quarter-2025-financial-results-november-4-2025-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-report-third-quarter-2025-financial-results-november-4-2025-2025-10</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK</description>
</item>
<item>
<title>Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-updated-data-partner-genfleet-therapeutics-phase-1-2</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-updated-data-partner-genfleet-therapeutics-phase-1-2</guid>
<pubDate>Sun, 19 Oct 2025 04:00:00 GMT</pubDate>
<description>GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at</description>
</item>
<item>
<title>Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-late-breaking-abstract-partner-genfleet-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-announces-late-breaking-abstract-partner-genfleet-therapeutics</guid>
<pubDate>Wed, 13 Aug 2025 04:00:00 GMT</pubDate>
<description>GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the recommended Phase 2 dose of 600 mg QD GFH375</description>
</item>
<item>
<title>Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates</title>
<link>https://6ix.com/company/verastem-inc/news/verastem-oncology-reports-second-quarter-2025-financial-results-and-highlights-recent</link>
<guid isPermaLink="true">https://6ix.com/company/verastem-inc/news/verastem-oncology-reports-second-quarter-2025-financial-results-and-highlights-recent</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $2.1 million in the first six weeks of launch First patient dosed in the U.S. trial for VS-7375,</description>
</item>
</channel>
</rss>